Effect of citicoline (CDP-choline) on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.

Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, 
Sabounjian L, Harnett K, Schwiderski U, Gammans R.

National Institute of Neurological Disorders and Stroke, 
National Institutes of Health,
Bethesda, MD 20892-4129.
Ann Neurol 2000 Nov;48(5):713-22


We examined the effect of the neuroprotective and neurorepairative agent CDP-choline on the growth of cerebral ischemic lesions in a double-blind placebo-controlled study involving patients with acute ischemic stroke using diffusion-weighted magnetic resonance imaging (DWI).  Patients with acute ischemic stroke symptom onset 24 hours or less before the start of treatment, National Institutes of Health Stroke Scale (NIHSS) scores of 5 or higher, and lesions of 1 to 120 cc in cerebral gray matter by DWI were enrolled. DWI, T2-weighted magnetic resonance imaging (MRI), perfusion-weighted MRI, and magnetic resonance angiography were obtained at baseline, week 1, and week 12. CDP-choline coline (500 mg/day) was administered orally for 6 weeks, and patients were followed for 12 weeks.  The primary assessment was progression of ischemic lesion volume from baseline to 12 weeks as measured by MRI. A total of 100 patients entered the study.  The primary MRI analysis included 40 placebo-treated patients and 41 CDP-choline-treated patients with both baseline and week 12 MRI data and failed to demonstrate a significant difference in lesion volume change from baseline to week 12. From baseline to week 12, ischemic lesion volume [all values mean (SE)] expanded by 180% (107) among placebo-treated patients compared with 34% (19) among CDP-choline-treated patients. In a secondary analysis, lesion volume decreased from week 1 to week 12 by 6.9 cc (2.8) on placebo versus 17.2 cc (2.6) on CDP-choline. Baseline variables that were predictors of change in lesion size over 12 weeks were the volume of hypoperfusion (strongest association), baseline NIHSS score, lesion volume on DWI, arterial lesion by magnetic resonance angiography, and categorized elapsed time (< or =12 or >12 hours) from stroke onset to first dose.  A marked association between lesion volume reduction and improvement of NIHSS score by seven or more points was observed.  Significant correlations between lesion volumes and clinical measures were found, replicating values reported in the literature for smaller case series.  We observed a reduction in lesion volume growth from baseline to week 12 with CDP-choline treatment, with a significantly greater reduction in volume from week 1 to week 12 with CDP-choline.  We found a significant inverse relationship between lesion volume change over 12 weeks as measured by MRI and clinical outcome for ischemic stroke.  This relationship supports the role of DWI as a surrogate marker of clinically meaningful lesion progression in stroke clinical trials. The hypothesis that CDP-choline reduces lesion growth and improves clinical outcome will be tested further.

 | Home | Order |

 1.   CDP choline  may be useful in the treatment of Alzheimer's
 2.   CDP choline  therapeutic effects in Alzheimer's
 3.   CDP choline  choline  effects on cognition in patients with Alzheimer's
 4.   CDP choline  significant improvement in Alzheimer's after 1 month  
 5.   CDP choline  improved mental performance in Alzheimer's
 6.   CDP choline  improvement in glaucoma
 7.   CDP choline  therapeutic value in the treatment of glaucoma
 8.   CDP choline  improved retinal responses in patients with glaucoma
 9.   CDP choline  in acute ischemic stroke
10.  CDP choline  randomized trial in acute ischemic stroke
11.  CDP choline  treatment after traumatic brain injury
12.  CDP choline  action and effects in ischemic brain injury